Hepatitis a disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HPT003 MIFTS: 62	Hepatitis a Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Nephrological diseases, Oral diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Hepatitis a

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a ¹¹ ⁷⁵ ⁴¹ ⁴³ ¹⁴ ⁷¹

Viral Hepatitis, Type a ¹¹

Viral Hepatitis a ¹¹

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases Genetic diseases Cancer diseases
Anatomical: Nephrological diseases Liver diseases Gastrointestinal diseases Immune diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Certain infectious and parasitic diseases

Viral hepatitis

Acute hepatitis A

Hepatitis A with hepatic coma

Hepatitis A without hepatic coma

External Ids:

Disease Ontology ¹¹ DOID:12549

MeSH ⁴³ D006506

NCIt ⁴⁹ C3096

SNOMED-CT ⁶⁸ 40468003

ICD10 ³¹ B15.0 B15.9

UMLS ⁷¹ C0019159

Sources

Summaries for Hepatitis a

MedlinePlus: ⁴¹ What is Hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. What is hepatitis A? Hepatitis A is a type of viral hepatitis. It causes an acute, or short-term, infection. This means that people usually get better without treatment after a few weeks. Thanks to a vaccine, hepatitis A is not very common in the United States. What causes hepatitis A? Hepatitis A is caused by the hepatitis A virus. The virus spreads through contact with an infected person's stool. This can happen if you: Eat food made by someone who has the virus and did not properly wash their hands after using the bathroom Drink contaminated water or eat foods that were rinsed with contaminated water Have close personal contact with someone who has hepatitis A. This could be through certain types of sex (like oral-anal sex), taking care of someone who is ill, or using illegal drugs with others. Who is at risk for hepatitis A? Although anyone can get hepatitis A, you are at higher risk if you: Travel to developing countries Have sex with someone who has hepatitis A Are a man who has sex with men Use illegal drugs Are experiencing homelessness Live with or care for someone who has hepatitis A Live with or care for a child recently adopted from a country where hepatitis A is common What are the symptoms of hepatitis A? Not everyone with hepatitis A has symptoms. Adults are more likely to have symptoms than children. If you do have symptoms, they usually start 2 to 7 weeks after infection. They can include: Dark yellow urine Diarrhea Fatigue Fever Gray- or clay-colored stools Joint pain Loss of appetite Nausea and/or vomiting Abdominal pain Yellowish eyes and skin, called jaundice The symptoms usually last less than 2 months, although some people can be ill for as long as 6 months. You are at a higher risk of getting a more severe infection from hepatitis A if you also have HIV, hepatitis B, or hepatitis C. What other problems can hepatitis A cause? In rare cases, hepatitis A may lead to liver failure. This is more common in adults over age 50 and in people who have another liver. How is hepatitis A diagnosed? To diagnose hepatitis A, your health care provider may use many tools: A medical history, which includes asking about your symptoms A physical exam Blood tests, including tests for viral hepatitis What are the treatments for hepatitis A? There is no specific treatment for hepatitis A. The best way to recover is to rest, drink plenty of liquids, and eat healthy foods. Your provider may also suggest medicines to help relieve symptoms. In more severe cases, you may need care in a hospital. Can hepatitis A be prevented? The best way to prevent hepatitis A is to get the hepatitis A vaccine. It is also important to have good hygiene, especially washing your hands thoroughly after you go to the bathroom. National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Hepatitis a, also known as viral hepatitis, type a, is related to hepatitis and fatty liver disease, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Levoleucovorin and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and t cells, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology: ¹¹ A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia: ⁷⁵ Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral... more...

Sources

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus	Hepatitis a
Hepatitis C	Viral Hepatitis
Hepatitis B	Hepatitis D
Autoimmune Hepatitis	Hepatitis E
Autoimmune Hepatitis Type 2	Autoimmune Hepatitis Type 1

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1196)

#	Related Disease	Score	Top Affiliating Genes
1	hepatitis	31.8	TNF TICAM1 SERPINA1 IKBKG IFNA1 HAVCR2
2	fatty liver disease	31.7	TNF IL1B IL10 GPT AFP
3	hepatitis e	31.7	TNF TLR3 IL10 IFNG GPT F2
4	viral hepatitis	31.6	SERPINA1 IL4 IFNG IFNA1 GPT F2
5	severe cutaneous adverse reaction	31.5	TNF IFNG GPT CTLA4 CD4
6	autoimmune hepatitis	31.2	TNF IL10 IFNG GPT F2 CTLA4
7	acute kidney failure	31.2	HAVCR1 GPT F2 ALB
8	cholecystitis	31.1	GPT F2 ALB
9	hepatic encephalopathy	31.1	TNF GPT F2 ALB
10	hepatitis b	30.9	TNF TLR3 IFNG IFNA1 GPT F2
11	liver disease	30.9	TNF SERPINA1 IFNA1 GPT F3 F2
12	alcoholic hepatitis	30.9	TNF IL1B IL10 IFNG GPT F2
13	acute pancreatitis	30.8	TNF IL1B IL10 GPT
14	hepatitis c	30.8	TLR3 IL10 IFNG IFNA1 GPT F2
15	typhoid fever	30.8	TNF IL1B IFNG GPT F2 ALB
16	syphilis	30.8	TNF GPT CD4 ALB
17	viral infectious disease	30.7	TNF TLR3 IL4 IL1B IL10 IFNG
18	hepatorenal syndrome	30.7	HAVCR1 GPT F2 ALB AFP
19	acute kidney tubular necrosis	30.7	TNF IL1B HAVCR1 GPT ALB
20	haemophilus influenzae	30.6	TNF IL1B
21	kidney disease	30.6	TNF IL1B IL10 IFNG F2 ALB
22	granulomatous hepatitis	30.5	TNF GPT CTLA4 CD4 ALB
23	pancreatitis	30.5	TNF SERPINA1 IL1B IL10 ALB
24	portal hypertension	30.5	TNF GPT F2 ALB AFP
25	ige responsiveness, atopic	30.5	IL4 IL10 IFNG
26	glomerulonephritis	30.5	TNF IL4 IL1B IL10 ALB
27	gastroenteritis	30.4	TNF IL4 IL1B IL10 IFNG IFNA1
28	interstitial nephritis	30.4	TNF HAVCR1 CD4 ALB
29	hypereosinophilic syndrome	30.4	IL4 IL10 IFNG IFNA1
30	vasculitis	30.4	TNF SERPINA1 IL1B IL10 CTLA4
31	tetanus	30.4	TNF IL4 IL1B IL10 IFNG ALB
32	henoch-schoenlein purpura	30.4	TNF CD4 ALB
33	glucosephosphate dehydrogenase deficiency	30.4	TNF IKBKG GYPA GPT ALB
34	mouth disease	30.4	TLR3 IL10 IFNG IFNA1
35	human cytomegalovirus infection	30.4	TNF IL10 CD4
36	hyperthyroidism	30.4	TNF GPT F2 CTLA4 ALB
37	diphtheria	30.3	TNF IL4 IL1B IFNG IFNA1 ALB
38	encephalitis	30.3	TNF TLR3 IL1B IL10 IFNA1
39	biliary atresia	30.3	IFNG GPT F2 ALB
40	pancytopenia	30.3	IFNG GPT F2 CD4 ALB
41	bowel dysfunction	30.3	TNF IL1B IL10 GPT ALB
42	aplastic anemia	30.3	TNF IL4 IL1B IL10 IFNG CD4
43	anemia, autoimmune hemolytic	30.3	IL10 GYPA CTLA4 CD4
44	mumps	30.3	TNF TLR3 IL1B IL10 IFNG IFNA1
45	drug-induced hepatitis	30.3	TNF GPT F2 CD4 ALB AFP
46	neuromyelitis optica	30.3	IL4 IL1B IFNA1
47	wilson disease	30.3	SERPINA1 GPT F2 ALB
48	inflammatory bowel disease 1	30.3	TNF IL1B IL10
49	graft-versus-host disease	30.2	TNF IL10 IFNG
50	alcoholic liver cirrhosis	30.2	TNF IL1B GPT F2 ALB AFP

Graphical network of the top 20 diseases related to Hepatitis a:

Sources

Symptoms & Phenotypes for Hepatitis a

Symptoms:

¹¹

• vomiting
• fatigue
• fever
• jaundice
• abdominal pain

• nausea
• loss of appetite
• joint pain
• clay-colored bowel movements

UMLS symptoms related to Hepatitis a:

nausea and vomiting; constipation; fever; abdominal pain; pruritus; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Hepatitis a according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.14	AFP ALB CD4 CTLA4 F2 F3
2	no effect	GR00402-S-2	10.14	ALB CD4 CTLA4 F2 F3 GYPA

MGI Mouse Phenotypes related to Hepatitis a:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.3	AFP ALB CD4 CTLA4 F2 F3
2	immune system	MP:0005387	10.22	ALB CD4 CTLA4 F2 F3 HAVCR1
3	neoplasm	MP:0002006	10.21	AFP ALB F3 IFNG IKBKG IL10
4	normal	MP:0002873	10.19	ALB CTLA4 F2 F3 IFNA1 IFNG
5	endocrine/exocrine gland	MP:0005379	10.17	AFP ALB CD4 CTLA4 F2 IFNG
6	cardiovascular system	MP:0005385	10.15	ALB CTLA4 F2 F3 HAVCR2 IFNG
7	liver/biliary system	MP:0005370	10.13	AFP ALB CTLA4 IFNG IKBKG IL10
8	digestive/alimentary	MP:0005381	10.1	ALB CD4 CTLA4 F2 IFNG IKBKG
9	hematopoietic system	MP:0005397	10.06	CD4 CTLA4 F2 F3 GYPA HAVCR1
10	respiratory system	MP:0005388	10	CTLA4 F2 F3 HAVCR1 IFNA1 IFNG
11	mortality/aging	MP:0010768	9.86	ALB CD4 CTLA4 F2 F3 HAVCR1
12	integument	MP:0010771	9.32	CD4 CTLA4 F2 F3 IFNG IKBKG

Sources

Drugs & Therapeutics for Hepatitis a

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 462)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Acarbose

Approved, Investigational

Phase 4

56180-94-0

441184 444254

Aluminium phosphate

Approved, Investigational

Phase 4

7784-30-7

Framycetin

Approved, Experimental, Vet_approved

Phase 4

1404-04-2, 119-04-0, 3947-65-7

413349 8378

Isoniazid

Approved, Investigational

Phase 4

54-85-3

3767

Pyrazinamide

Approved, Investigational

Phase 4

98-96-4

1046

Rifampicin

Approved

Phase 4

13292-46-1

135512673 5381226 135900090

Aluminum sulfate

Approved

Phase 4

10043-01-3

Milk thistle

Approved, Experimental, Investigational

Phase 4

65666-07-1

Aluminum hydroxide

Approved, Investigational

Phase 4

21645-51-2

Racivir

Approved, Investigational

Phase 4

143491-57-0, 143491-54-7

60877

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Nitazoxanide

Approved, Investigational, Vet_approved

Phase 4

55981-09-4

41684

Simethicone

Approved

Phase 4

8050-81-5

Metformin

Approved

Phase 4

1115-70-4, 657-24-9

4091

Acetylcarnitine

Approved, Investigational

Phase 4

3040-38-8

Nevirapine

Approved

Phase 4

129618-40-2

4463

Zidovudine

Approved

Phase 4

30516-87-1

35370

Colchicine

Approved

Phase 4

64-86-8

2833 6167

Iron

Approved

Phase 4

7439-89-6

29936

Chloroquine

Approved, Investigational, Vet_approved

Phase 4

54-05-7

2719

Rituximab

Approved

Phase 4

174722-31-7

Everolimus

Approved

Phase 4

159351-69-6

70789204 6442177

Sirolimus

Approved, Investigational

Phase 4

53123-88-9

5284616 6436030

Citalopram

Approved

Phase 4

59729-32-7, 59729-33-8

2771

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 11128-99-7, 4474-91-3

172198

Orlistat

Approved, Investigational

Phase 4

96829-58-2

3034010

Nelfinavir

Approved

Phase 4

159989-64-7

64143

Losartan

Approved

Phase 4

114798-26-4

3961

Cobicistat

Approved

Phase 4

1004316-88-4

24950485 25151504

Elvitegravir

Approved

Phase 4

697761-98-1

23083982 5277135

Azathioprine

Approved

Phase 4

446-86-6

2265

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Empagliflozin

Approved

Phase 4

864070-44-0

73151030 11949646

Pioglitazone

Approved, Investigational

Phase 4

111025-46-8

4829

Ezetimibe

Approved

Phase 4

163222-33-1

150311

Pancrelipase

Approved, Investigational

Phase 4

53608-75-6

8519

Parathyroid hormone

Approved, Investigational

Phase 4

9002-64-6

Calcium carbonate

Approved, Investigational

Phase 4

471-34-1

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Mycophenolic acid

Approved, Investigational

Phase 4

24280-93-1

446541

Buprenorphine

Approved, Illicit, Investigational, Vet_approved

Phase 4

52485-79-7, 53152-21-9

644073 40400

Methadone

Approved

Phase 4

76-99-3, 1095-90-5

4095

Interferon alfacon-1

Approved, Investigational

Phase 4

118390-30-0

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Rosiglitazone

Approved, Investigational

Phase 4

122320-73-4, 155141-29-0

77999

Interventional clinical trials:

(show top 50) (show all 2744)

#	Name	Status	NCT ID	Phase	Drugs
1	Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan	Unknown status	NCT03855176	Phase 4	Vaqta Injectable Product
2	Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine in HIV-exposed and HIV-unexposed South African Children	Unknown status	NCT03330171	Phase 4
3	Immune Response to Pneumococcal Conjugate Vaccine in Adults Receiving Hepatitis A Vaccine at the Same Time	Unknown status	NCT01926860	Phase 4
4	Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines	Unknown status	NCT03231605	Phase 4
5	A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial	Unknown status	NCT01965418	Phase 4	Fufang Biejia Ruangan Tablet;Placebo
6	Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B	Unknown status	NCT01906580	Phase 4	Peg-IFNα-2a;Entecavir
7	The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B	Unknown status	NCT03349008	Phase 4	Entecavir;Magnesium Isoglycyrrhizinate;Diammonium Glycyrrhizinate;Magnesium Isoglycyrrhizinate Placebo;Diammonium Glycyrrhizinate Placebo
8	Prospective, Multicenter, Randomized, and Comparative Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes	Unknown status	NCT04584242	Phase 4	gluconon tab 15mg;suganon tab 5mg
9	The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates	Unknown status	NCT02764671	Phase 4
10	The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma	Unknown status	NCT00834860	Phase 4	peginterferon alpha-2a and ribavirin
11	Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis	Unknown status	NCT02971306	Phase 4	standard medical therapy;G-CSF;n-Acetylcysteine
12	Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase	Unknown status	NCT01833611	Phase 4	Entecavir;placebo
13	Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients	Unknown status	NCT03332329	Phase 4	Entecavir;Granulocyte Macrophage Colony Stimulating Factor;Y peginterferon alfa-2b;HBV vaccine
14	Granulocyte Colony Stimulating Factor in Alcoholic Hepatitis	Unknown status	NCT03703674	Phase 4	GCSF
15	Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)	Unknown status	NCT02768545	Phase 4	Ezetimibe
16	Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma	Unknown status	NCT00768157	Phase 4	antiviral treatment (lamivudine or entecavir)
17	Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.	Unknown status	NCT02108301	Phase 4	tacrolimus-cyclosporine A
18	Randomized, Multicenter, Open -Label Clinical Trial to Study the Effect of Adding on Pegylated Interferon Therapy for Patients Diagnosed With Chronic Hepatitis B Showing Maintained Response While Receiving Ongoing Nucleotide Analogues	Unknown status	NCT02982837	Phase 4	PEG-IFN & Nucleos(t)tide analogues;Nucleos(t)tide analogues
19	Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial	Unknown status	NCT01907230	Phase 4	Entecavir
20	A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR)	Unknown status	NCT01896609	Phase 4	Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
21	Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial	Unknown status	NCT00663182	Phase 4	Entecavir
22	Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)	Unknown status	NCT03888729	Phase 4	sofosbubir/velpatasvir;sofosbubir/velpatasvir/voxilaprevir
23	The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg(I-Cure-3X)	Unknown status	NCT03801538	Phase 4	Peginterferon Alfa;Nucleoside Analog (Substance)
24	Localized on -Site Testing and Treatment of Hepatitis C in Homeless Persons in South London: a Pilot Non-randomised Phase 4 Interventional Clinical Trial of Grazoprevir and Elbasvir ± Ribavirin in Participants With Genotype 1a, 1b or 4 to Measure Efficacy and Adherence to Treatment in a Homeless Population	Unknown status	NCT03797066	Phase 4	ZEPATIER 50Mg-100Mg Tablet
25	Screening for Hepatitis C and Hepatitis B in Inpatients: A Toronto Viral Hepatitis Care Network (VIRCAN) Collaboration	Unknown status	NCT04620226	Phase 4
26	Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents.	Unknown status	NCT02745132	Phase 4
27	Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy	Unknown status	NCT02638233	Phase 4	Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
28	Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues	Unknown status	NCT01911156	Phase 4	Continue NA treatment;Discontinue NA Treatment
29	Investigator Initiated Study of Thymosin in HBV-related HCC	Unknown status	NCT02281266	Phase 4	thymalfasin;nucleoside analog (suggest to use entecavir)
30	Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus	Unknown status	NCT03695029	Phase 4	Tenofovir Alafenamide
31	Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study	Unknown status	NCT02639585	Phase 4	Daclinza and Sunvepra
32	A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase	Unknown status	NCT00823550	Phase 4	Entecavir;Lamivudine
33	A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B	Unknown status	NCT00778596	Phase 4	Prednisolone;Placebo priming
34	Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis	Unknown status	NCT02024295	Phase 4	Ademethionine;Polyene Phosphatidyl choline
35	Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor	Unknown status	NCT02973646	Phase 4	Entecavir or Tenofovir;Peginterferon Alfa-2B
36	A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus	Unknown status	NCT02241590	Phase 4	Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
37	A Real-World Study of Sequential Combination Therapy With Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B	Unknown status	NCT03357822	Phase 4	Pegylated interferon;Entecavir;Tenofovir disoproxil fumarate
38	Efficacy and Safety of Switching to Tenofovir Alafenamide for Chronic Hepatitis B Patients With Advanced Fibrosis and Partial Virologic Responses to Oral Nucleos(t)Ide Analogues	Unknown status	NCT03798119	Phase 4	Tenofovir Alafenamide
39	A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection	Unknown status	NCT02759861	Phase 4	harvoni
40	The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg	Unknown status	NCT02745704	Phase 4	Peginterferon alfa
41	Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients	Unknown status	NCT02588937	Phase 4	EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
42	The Effects of Preventive Versus on Demand Nutritional Advice and Support on the Nutritional Status of Patients During Antiviral Therapy for Hepatitis C A Randomized, Multi Center Trial	Unknown status	NCT00841243	Phase 4
43	Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis	Unknown status	NCT01998620	Phase 4	Ademetionine 2;Ademetionine 1;Ademetionine 3
44	Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF	Unknown status	NCT02957994	Phase 4	Tenofovir alafenamide fumarate
45	Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B	Unknown status	NCT01925820	Phase 4	Pegasys&Entecavir
46	Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant	Unknown status	NCT03359746	Phase 4	Grazoprevir/Elbasvir
47	The Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4	Unknown status	NCT03743727	Phase 4	Combined therapy LDV and SOF
48	Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine	Unknown status	NCT02774837	Phase 4	Tenofovir disoproxil;Telbivudine
49	Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C	Unknown status	NCT03022006	Phase 4	elbasvir, grazoprevir
50	A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta	Unknown status	NCT00117533	Phase 4	pegylated IFN alfa-2b plus ribavirin

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Sources

Genetic Tests for Hepatitis a

Sources

Anatomical Context for Hepatitis a

Organs/tissues related to Hepatitis a:

FMA: Liver

MalaCards : Liver, Kidney, T Cells, Skin, Placenta, Myeloid, Bone Marrow

Sources

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 13170)

#	Title	Authors	PMID	Year
1	Hepatitis A virus seroprevalence among children and adolescents in a high-burden HIV setting in urban South Africa. ⁶² ⁴¹	du Plessis NM...Avenant T	36450802	2022
2	Hepatitis A and hepatitis B infection risk among employees at schools for disabled pupils. ⁶² ⁴¹	Lang F...Kegel P	36424401	2022
3	Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation. ⁴¹	Elsebaey MA...Ismail AAM	36451458	2022
4	Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study. ⁶²	Krogvold L...Toniolo A	35953727	2022
5	Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. ⁶²	Degasperi E...Lampertico P	35973578	2022
6	Endemicity change of hepatitis A infection necessitates vaccination in food handlers: An Indian perspective. ⁶²	Shenoy B...Mazumdar J	33595412	2022
7	Calcineurin Inhibitors in the Treatment of Adult Autoimmune Hepatitis: A Systematic Review. ⁶²	Baven-Pronk MA...Dutch Autoimmune Hepatitis Study Group	36381101	2022
8	Seroprevalence of Hepatitis A, B and C Among a Sample of Refugees in Egypt: An Exploratory Survey. ⁶²	El-Ghitany EM...Omran EA	36107333	2022
9	Comparative transcriptome reveals the effect of IFITM1 on differential resistance to duck hepatitis A virus genotype 3 in Pekin ducks. ⁶²	Liang S...Hou S	36130655	2022
10	The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy. ⁶²	Chen S...Yang J	35044877	2022
11	Hepatocellular Injury in Children Treated for Rifampicin-resistant Tuberculosis: Incidence, Etiology and Outcome. ⁶²	Duvenhage J...Schaaf HS	36102699	2022
12	Implementation of EACS vaccination recommendations among people living with HIV. ⁶²	Breitschwerdt S...Boesecke C	35522383	2022
13	Treatment of hospital wastewater by electron beam technology: Removal of COD, pathogenic bacteria and viruses. ⁶²	Wang J...Lin J	36055595	2022
14	Incidence trends of acute viral hepatitis caused by four viral etiologies between 1990 and 2019 at the global, regional and national levels. ⁶²	Ouyang G...Wen Y	36214561	2022
15	[(Rare) infectious hepatitis as an important differential diagnosis of unclear hepatopathy]. ⁶²	Wuhrl M...Mogler C	36456751	2022
16	Treatment effects of phosphorylated Chrysanthemum indicum polysaccharides on duck viral hepatitis by protecting mitochondrial function from oxidative damage. ⁶²	Qiu T...Liu J	36395693	2022
17	A case of hepatitis induced by herbal medicine in non-small cell lung cancer patient treated by a combination of immunotherapy and chemotherapy. ⁶²	Lopes S...Benedicte G	35484834	2022
18	Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation. ⁶²	Wolf AS...Swarthout TD	36210249	2022
19	Epidemiology and Risk Factors for Acute Viral Hepatitis in Bangladesh: An Overview. ⁶²	Kayesh MEH...Tsukiyama-Kohara K	36422336	2022
20	Modeling long-term persistence after 8 years of hepatitis B booster vaccination in 5- to 15-year-old children. ⁶²	Qiu Y...Ren JJ	35507912	2022
21	Impact of a Targeted Intervention on Hepatitis C Care Among African Americans With Serious Mental Illness. ⁶²	Heinlein E...Himelhoch S	35473365	2022
22	Attractive and healthy-looking male faces do not show higher immunoreactivity. ⁶²	Patkova Z...Havlicek J	36319732	2022
23	Nonlytic Quasi-Enveloped Hepatovirus Release Is Facilitated by pX Protein Interaction with the E3 Ubiquitin Ligase ITCH. ⁶²	Shirasaki T...Lemon SM	36286484	2022
24	The Association of Glycemic Index, Glycemic Load, and Daily Carbohydrates Intake with the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. ⁶²	Yang LS...Li T	36411493	2022
25	A link between severe hepatitis in children and adenovirus 41 and adeno-associated virus 2 infections. ⁶²	Grand RJ	36367762	2022
26	Medical screening tests and vaccination among hospital-based physicians in Israel. ⁶²	Eltalakat S...Treister-Goltzman Y	36357854	2022
27	Wide Variability in Documentation of Sexual Orientation, Gender Identity, and Preventive Health Screenings in a Diverse Sample of U.S. Community Health Centers. ⁶²	Mayer KH...Grasso C	35772015	2022
28	Macrophage Depletion Reactivates Fecal Virus Shedding following Resolution of Acute Hepatitis A in Ifnar1-/- Mice. ⁶²	Shiota T...Hirai-Yuki A	36354341	2022
29	Hepatitis A in the Eastern Mediterranean Region: a comprehensive review. ⁶²	Badur S...Saha D	35617508	2022
30	A combined inactivated cholera and hepatitis A vaccine-induced potent protective immunity in a mouse model. ⁶²	AbdelAllah NH...Gaber Y	36269328	2022
31	Decreasing Trends in the Incidence of Age- and Sex-specific Hepatitis A Virus Infection in Hunan Province, China, from 2004-2020: A Joinpoint Analysis. ⁶²	Yang RJ...Zang S	36443258	2022
32	Crystal digital RT-PCR for the detection and quantification of norovirus and hepatitis A virus RNA in frozen raspberries. ⁶²	Larocque E...Lambert D	36055105	2022
33	Monkeypox, severe hepatitis A, and syphilis in an HIV returning traveler from Spain to Romania. ⁶²	Oprea C...Florescu SA	36089283	2022
34	2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: A too early endpoint? ⁶²	Medas R...Macedo G	35716845	2022
35	Ethnic differences in hepatitis A and E virus seroprevalence in patients attending the Emergency Department, Paramaribo, Suriname. ⁶²	Mac Donald-Ottevanger MS...Boyd A	36353973	2022
36	Seroepidemiology of hepatitis A virus infection in Japan: An area of very low endemicity. ⁶²	Kiyohara T...Muramatsu M	36333781	2022
37	HIV PrEP and viral hepatitis: a unique opportunity for integration. ⁶²	Schaefer R...Luhmann N	36332650	2022
38	An electronic medical record-based intervention to improve hepatitis A vaccination rates in the emergency department during a regional outbreak. ⁶²	Bukhsh MA...Swaminathan L	36410781	2022
39	Shifting Hepatitis A Epidemiology Requires Renewed Vaccination Efforts. ⁶²	Kuehn BM	36346409	2022
40	A custom hepatitis A virus assay for whole-genome sequencing. ⁶²	Cleary NG...St George K	36375537	2022
41	WHO Backs Single Dose of Hepatitis A Vaccine in Some Cases. ⁶²	Larkin HD	36378201	2022
42	Duck hepatitis A virus prevalence in mainland China between 2009 and 2021: A systematic review and meta-analysis. ⁶²	Zhou S...Zhang T	35964373	2022
43	Portosystemic shunt, a rare cause of neonatal cholestatic hepatitis. A case report. ⁶²	Geffner SC...Carrascal Gutierrez MP	36378196	2022
44	A high-dimensional cytometry atlas of peripheral blood over the human life span. ⁶²	Jalali S...Pellicci DG	36218032	2022
45	Prevalence of enteric viruses in wastewater in Egypt after the COVID-19 pandemic. ⁶²	Abd-Elshafy DN...Bahgat MM	36448616	2022
46	Adult Vaccination. ⁶²	Greenberg GM...Hanson MJS	36379499	2022
47	Exotic viral hepatitis: A review on epidemiology, pathogenesis, and treatment. ⁶²	van Leeuwen LPM...Goeijenbier M	35817222	2022
48	Clinical features and outcomes of opsoclonus myoclonus ataxia syndrome. ⁶²	Yildirim M...Anlar B	36155293	2022
49	Effect of an Integrated Transplantation Mental Health Program on Alcohol Relapse After Liver Transplantation for Severe Alcoholic Hepatitis: A Single-Center Prospective Study. ⁶²	Zanowski SC...Hong JC	36411097	2022
50	RIPK3 modulates sarcoma through immune checkpoint HAVCR2. ⁶²	Qian C...Du J	36238358	2022

Sources

Genes for Hepatitis a

Genes related to Hepatitis a (0 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	HAVCR1	Hepatitis A Virus Cellular Receptor 1	Protein Coding	55.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Summaries Proteins Functions (show sections)
2	HAVCR2	Hepatitis A Virus Cellular Receptor 2	Protein Coding	34.02	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Proteins (show sections)
3	TICAM1	TIR Domain Containing Adaptor Molecule 1	Protein Coding	19.55	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Proteins (show sections)
4	GYPA	Glycophorin A (MNS Blood Group)	Protein Coding	18.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
5	IKBKG	Inhibitor Of Nuclear Factor Kappa B Kinase Regulatory Subunit Gamma	Protein Coding	18.67	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Proteins (show sections)
6	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	16.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	F2	Coagulation Factor II, Thrombin	Protein Coding	15.48	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	ALB	Albumin	Protein Coding	15.06	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	CD4	CD4 Molecule	Protein Coding	14.59	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	SERPINA1	Serpin Family A Member 1	Protein Coding	14.12	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	AFP	Alpha Fetoprotein	Protein Coding	14.07	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	TNF	Tumor Necrosis Factor	Protein Coding	14.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	IFNA1	Interferon Alpha 1	Protein Coding	13.92	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	IFNG	Interferon Gamma	Protein Coding	13.64	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	IL10	Interleukin 10	Protein Coding	13.52	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	F3	Coagulation Factor III, Tissue Factor	Protein Coding	13.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	13.19	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	IL1B	Interleukin 1 Beta	Protein Coding	13.11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	IL4	Interleukin 4	Protein Coding	13.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	TLR3	Toll Like Receptor 3	Protein Coding	13.02	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	MAVS	Mitochondrial Antiviral Signaling Protein	Protein Coding	12.82	DISEASES inferred ¹⁴ GeneCards inferred via : Proteins (show sections)
22	TLR4	Toll Like Receptor 4	Protein Coding	12.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	CCR5	C-C Motif Chemokine Receptor 5	Protein Coding	12.78	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	PDCD1	Programmed Cell Death 1	Protein Coding	12.68	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	12.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	CYP3A4	Cytochrome P450 Family 3 Subfamily A Member 4	Protein Coding	12.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	CXCL10	C-X-C Motif Chemokine Ligand 10	Protein Coding	12.18	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	IFNA2	Interferon Alpha 2	Protein Coding	12.14	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	G6PD	Glucose-6-Phosphate Dehydrogenase	Protein Coding	12.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Hepatitis a

Sources

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

Sources

Pathways for Hepatitis a

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

(show top 50) (show all 59)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.91	TNF TLR3 TICAM1 SERPINA1 IL4 IL1B
2	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.65	TNF IL4 IL1B IL10 IKBKG IFNG
3	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.57	TNF IL4 IL1B IL10 IKBKG IFNG
4	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.42	TNF TLR3 IL4 IL1B IL10 IKBKG
5	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.34	TNF IL4 IL1B IL10 IKBKG IFNG
6	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.89	IFNA1 IKBKG IL1B TICAM1 TLR3 TNF
7	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.7	TNF IL1B IKBKG IFNG CD4
8	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.67	TNF IL4 IL1B IL10 IFNG IFNA1
9	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.55	TNF IL1B IL10 IKBKG IFNG F2
10	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.53	TNF TLR3 TICAM1 IL1B IKBKG IFNA1
11	DDX58/IFIH1-mediated induction of interferon-alpha/beta ⁶⁶ Show member pathways Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²² Negative regulators of DDX58/IFIH1 signaling ⁶⁶ NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 ⁶⁶ Novel intracellular components of RIG-I-like receptor pathway ⁷⁴ SARS-CoV-2 B.1.1.7 variant antagonises innate immune activation ⁷⁴ TRAF3-dependent IRF activation pathway ⁶⁶ TRAF6 mediated IRF7 activation ⁶⁶	12.49	TLR3 TICAM1 IKBKG IFNG IFNA1
12	Cytosolic sensors of pathogen-associated DNA ⁶⁶ Show member pathways Cytosolic DNA-sensing pathway ⁷⁴ DEx/H-box helicases activate type I IFN and inflammatory cytokines production ⁶⁶ IkBA variant leads to EDA-ID ⁶⁶ IRF3 mediated activation of type 1 IFN ⁶⁶ IRF3-mediated induction of type I IFN ⁶⁶ LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production ⁶⁶ Regulation by TREX1 ⁶⁶ Regulation of innate immune responses to cytosolic DNA ⁶⁶ RIP-mediated NFkB activation via ZBP1 ⁶⁶ Selenium micronutrient network ⁷⁴ STAT6-mediated induction of chemokines ⁶⁶ STING mediated induction of host immune responses ⁶⁶ ZBP1(DAI) mediated induction of type I IFNs ⁶⁶	12.45	TLR3 TICAM1 IL1B IKBKG IFNA1
13	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.45	TNF IL4 IL1B IKBKG IFNG
14	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) ⁶⁶ Show member pathways Post-translational protein phosphorylation ⁶⁶	12.39	SERPINA1 F2 ALB AFP
15	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.35	TNF TLR3 TICAM1 IL1B IKBKG IFNG
16	Neuroinflammation and glutamatergic signaling ⁷⁴	12.14	TNF IL4 IL1B IL10 IFNG
17	Spinal cord injury ⁷⁴	12.04	TNF IL4 IL1B IFNG
18	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	12.02	IL4 IL1B IFNG CD4
19	Interleukin-4 and Interleukin-13 signaling ⁶⁶	12	TNF IL4 IL1B IL10
20	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.95	TNF IL4 IL10 IFNG GYPA CD4
21	NF-kappaB Signaling ³	11.92	TNF TLR3 TICAM1 IL4 IL1B IL10
22	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.89	TLR3 IL4 IL1B IFNG CD4
23	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	11.88	TNF IL4 IL10 IKBKG IFNG CTLA4
24	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.85	TNF TLR3 IL1B IL10 IFNG CD4
25	Acute viral myocarditis ⁷⁴	11.82	TLR3 IL10 IFNG CD4
26	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.8	F3 IFNG IKBKG IL1B TNF
27	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.79	TNF IL4 IL10 IFNG
28	Glucocorticoid receptor regulatory network ⁶¹	11.78	IL4 IFNG AFP
29	Th17 cell differentiation pathway ⁷⁴	11.77	IL4 IL1B IFNG CD4
30	Allograft rejection ⁷⁴	11.77	CTLA4 IFNG IL10 IL1B IL4 TNF
31	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.75	TNF IL4 IFNG CTLA4
32	AP-1 transcription factor network ⁶¹	11.73	IL4 IL10 IFNG
33	Lung fibrosis ⁷⁴	11.72	IL1B IL4 SERPINA1 TNF
34	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.72	TNF IL1B IL10 IFNG CD4
35	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.69	TNF IL1B IFNG
36	miRNAs involvement in the immune response in sepsis ⁷⁴	11.68	TNF IL10 IKBKG
37	IL 10 signaling pathway ⁶⁷	11.68	TNF IL1B IL10
38	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.68	TNF IL4 IL10 IFNG
39	Innate Lymphoid Cells Differentiation ⁶⁵	11.64	TNF IL4 IL1B IL10 IFNG CD4
40	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.59	TNF IL10 HAVCR2
41	MSP-RON Signaling ⁶⁴	11.56	TNF IL1B IFNG
42	Th2 Differentiation ⁶⁵	11.56	IL4 IL10 IFNG CD4
43	Interleukin-10 signaling ⁶⁶	11.55	TNF IL1B IL10
44	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.53	IFNG IL1B TNF
45	Fibrin complement receptor 3 signaling pathway ⁷⁴	11.52	TNF TLR3 TICAM1 IKBKG
46	FOXA2 and FOXA3 transcription factor networks ⁶¹ Show member pathways FOXA transcription factor networks ⁶¹	11.51	F2 ALB AFP
47	THC Differentiation Pathway ⁶⁴	11.51	TNF IL4 IL10 IKBKG IFNG CD4
48	Heparin-induced Thrombocytopenia Pathway, Adverse Drug Reaction ⁶⁰	11.44	CD4 F2 F3 IL10
49	IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵ Show member pathways IL-2 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.43	TNF IL10 IFNG
50	IL-10 Pathway ⁶⁴	11.41	TNF IL1B IL10

Sources

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.72	TNF TLR3 SERPINA1 IL4 IL1B IL10

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 41)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.43	TNF TLR3 TICAM1 IL4 IL1B IFNG
2	inflammatory response	GO:0006954	10.39	TNF TLR3 TICAM1 IL1B IKBKG HAVCR2
3	positive regulation of NF-kappaB transcription factor activity	GO:0051092	10.27	TNF TLR3 TICAM1 IL1B IKBKG
4	positive regulation of inflammatory response	GO:0050729	10.24	IFNG IL1B TLR3 TNF
5	cellular response to lipopolysaccharide	GO:0071222	10.24	TNF TICAM1 IL1B IL10 HAVCR2
6	positive regulation of tumor necrosis factor production	GO:0032760	10.23	TLR3 TICAM1 IFNG HAVCR2
7	response to virus	GO:0009615	10.21	TNF TLR3 IKBKG IFNG
8	positive regulation of type II interferon production	GO:0032729	10.2	HAVCR2 IL1B TLR3 TNF
9	positive regulation of NIK/NF-kappaB signaling	GO:1901224	10.18	HAVCR2 IL1B TLR3 TNF
10	positive regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043123	10.18	TNF TLR3 TICAM1 IL1B IKBKG CD4
11	negative regulation of T cell proliferation	GO:0042130	10.16	IL10 HAVCR2 CTLA4
12	positive regulation of interleukin-8 production	GO:0032757	10.16	TNF TLR3 IL1B F3
13	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.15	TNF TICAM1 IL1B
14	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.14	F2 IL10 TNF
15	regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043122	10.14	TNF IL1B IKBKG
16	response to exogenous dsRNA	GO:0043330	10.14	TLR3 TICAM1 IFNA1
17	positive regulation of interleukin-6 production	GO:0032755	10.13	IFNG IL1B TICAM1 TLR3 TNF
18	positive regulation of nitric oxide biosynthetic process	GO:0045429	10.06	TNF TICAM1 IL1B IFNG
19	positive regulation of membrane protein ectodomain proteolysis	GO:0051044	10.02	TNF IL1B IFNG
20	positive regulation of heterotypic cell-cell adhesion	GO:0034116	10.01	TNF IL1B IL10
21	macrophage activation involved in immune response	GO:0002281	10	HAVCR2 IFNG TICAM1
22	immune response	GO:0006955	10	TNF TLR3 IL4 IL1B IL10 IKBKG
23	astrocyte activation	GO:0048143	9.99	IFNG IL1B TNF
24	positive regulation of mononuclear cell migration	GO:0071677	9.98	TNF IL4
25	negative regulation of cytokine production involved in immune response	GO:0002719	9.98	TNF IL10
26	positive regulation of fever generation	GO:0031622	9.98	TNF IL1B
27	positive regulation of MHC class II biosynthetic process	GO:0045348	9.97	IL4 IL10 IFNG
28	microglial cell activation	GO:0001774	9.97	TNF TLR3 IL4 IFNG
29	I-kappaB kinase/NF-kappaB signaling	GO:0007249	9.97	TNF TLR3 TICAM1 IL1B IKBKG
30	regulation of isotype switching	GO:0045191	9.96	IL4 IL10
31	sequestering of triglyceride	GO:0030730	9.95	TNF IL1B
32	toll-like receptor 3 signaling pathway	GO:0034138	9.95	TNF TLR3 HAVCR2
33	positive regulation of nitrogen compound metabolic process	GO:0051173	9.93	TNF IFNG
34	negative regulation of myeloid dendritic cell activation	GO:0030886	9.92	IL10 HAVCR2
35	positive regulation of vitamin D biosynthetic process	GO:0060557	9.91	TNF IFNG
36	chronic inflammatory response to antigenic stimulus	GO:0002439	9.91	TNF IL10
37	hemostasis	GO:0007599	9.81	SERPINA1 F3 F2
38	MyD88-independent toll-like receptor signaling pathway	GO:0002756	9.79	TLR3 TICAM1
39	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.73	IFNG IL1B TNF
40	positive regulation of cytokine production	GO:0001819	9.61	TNF TLR3 IL1B IL10 IFNG HAVCR2
41	positive regulation of chemokine production	GO:0032722	9.36	TNF TLR3 TICAM1 IL1B IFNG HAVCR2